MedTrace Logo

Superior Venous Access, Midline vs Ultrasound IVs

NCT03440944 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2021-04-29

Study results available
· View outcomes & findings →

Summary

Obtaining intravenous access (IVA) is the most common procedure performed in the emergency department (ED). Placement of IVA allows for blood work and delivery of intravenous fluids and medications. The implementation of ultrasound guided peripheral IVs (UGPIV) have allowed for ultrasound to be used to place an IV into patients with difficult vein access (DVA). An alternative device to place is a midline catheter (MC). The use of MCs against UGPIV has not been compared in a randomized study. Aim 1: To determine if UGPIVs have a higher failure rate than midline catheters within 72 hours of placement. Aim 2: To collect information to perform a direct cost analysis of UGPIV against that of the midline catheter. Aim 3: Assess patient satisfaction.

Conditions

  • Vascular Access Complication
  • Ultrasound Therapy; Complications

Interventions

DEVICE

Ultrasound Guided Peripheral IV Catheter

Patients randomized to this arm will receive an ultrasound guided peripheral IV catheter.

DEVICE

Midline Catheter

Patients randomized to this group will receive a midline catheter. The catheter is 10cm in length.

Sponsors & Collaborators

  • Society for Academic Emergency Medicine

    collaborator OTHER

  • Bard Peripheral Vascular, Inc.

    collaborator INDUSTRY

  • Boston Medical Center

    lead OTHER

Principal Investigators

  • Joseph Pare, MD MHS RDMS · Boston Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-23
Primary Completion
2021-01-25
Completion
2021-01-25
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03440944 on ClinicalTrials.gov